NeuroVision is developing numerous fluid biomarkers for the field of neurology. Many markers of neurodegeneration are present in the blood. Proteins such as amyloid beta (Aβ), tau, neurofilament-light (NfL), alpha-Synuclein, glial fibrillary acidic protein (GFAP) and others that represent abnormal pathology, synaptic dysfunction, inflammation, and blood-brain barrier regulation are available for measurement in plasma using highly accurate assays. NeuroVision is developing a family of neurodegenerative assays that when used singly or together in various multiplex combinations can help doctors assess a patient’s condition more accurately or more cost effectively that methods currently available
Retina-based prediction of brain amyloid status
Autofluorescent (AF) amyloid beta (Aβ) deposits appear in the retina concurrently with the brain and can be imaged non-invasively with a high-resolution ophthalmic instrument16, and there is potential to visualize amyloid at an earlier point in disease progression based on histologic evidence showing retinal amyloid’s existence in early-stage cases of disease – probable and possible Alzheimer’s Disease.10 Retinal amyloid assessment of brain amyloid status has potential clinical utility in patients being evaluated for dementia when used as a screening test to help identify those who may require an amyloid PET scan for ruling out an Alzheimer’s diagnosis, and for helping identify subjects for inclusion in clinical studies.
Color Fundus Image Analysis
NeuroVision is developing another AI software product intended for importing, processing and displaying of retinal images and for the measurement of ocular features in those images of the retina, with the goal of allowing doctors to practice best-in-class medicine through better identification and management of retinal diseases. There are many diseases that may affect the a person's eyesight. Two of the most prevalent are age-related macular degeneration and diabetic retinopathy, which combine to cause loss of eyesight in millions of people worldwide. The earliest signs of each disease are very small abnormalities that develop in the retina. Robust image processing and analysis has the potential to allow for early retinal disease detection. Enhanced visualization and quantification of abnormal retinal features may improve single visit identification as an aid in diagnosing and monitoring of disease over time.
Color Fundus Image
Green-channel with bright and dark abnormal retinal features segmented
Investigational Device(s). Limited by Federal (or United States) law to investigational use.